Intertek Expands GLP Bioanalytical Centre of Excellence In San Diego, California
10/21/2015
According to company officials, its expansion in capacity and new technology of the San Diego facility, which spans 46,000 square feet of laboratories, offices and sample storage, will benefit customers involved in preclinical and clinical development of small molecule drugs and biologic medicines. Investment in new bioanalytical technologies further strengthens capabilities to expedite delivery of fast and cost-effective bioanalysis results for global clients.
Mark Hammond, Intertek Pharmaceutical Services Business Leader said, “Our expanded GLP Bioanalytical Centre of Excellence in San Diego and new technologies provide a broader range of bioanalytical, biomarker, and cell-based capabilities services to meet our clients’ needs in preclinical and clinical bioanalysis, helping them to understand the safety, efficacy and mechanism of action of their small and large molecule drugs in development.”
Chetan Parmar, Senior Vice President of Intertek Life Sciences, said, “With recent expansion in bioanalytical capabilities in both the US and Europe, we further strengthen our capability to address the challenges our clients encounter during drug development through delivery of excellent global bioanalytical services."
The facility offers new technologies such as flow cytometry which will provide clients with robust and comprehensive analysis of cells to help understand the mechanism of action of drugs and facilitate evaluation of drug stability and potency. Furthermore, flow cytometry opens up an additional platform for assessing cell based neutralizing antibody activity in clinical trials, which is important in assessing any potential adverse immunological effects.
Luminex, another new technology at this site, will build on current high throughput and multiplexing capabilities to allow customised measurement of up to 100 analytes simultaneously using very small volumes of sample, officials said. This is ideal for studies where there is limited sample volume. Additional investment in new state-of-the-art liquid chromatography- mass spectrometry instruments not only upgrade Intertek's small molecule bioanalysis capabilities but also improve sensitivity and mass range for analysis of protein therapeutics.
Project Announcements
Piramal Pharma Solutions Expands Lexington, Kentucky, Operations
10/04/2024
G&H Decoys Plans Corning, Arkansas, Headquarters-Manufacturing Operations
10/04/2024
Britain-Based Ultimate Defense Technologies Establishes Billings, Montana, Operations
10/04/2024
Google Plans Dorchester County, South Carolina, Data Center Operations
10/04/2024
Sirius Analysis Plans Virginia Beach, Virginia, Headquarters
10/04/2024
South Korea-Based ILJIN Plans Auburn, Alabama, Manufacturing Operations
10/04/2024
Most Read
-
Top States for Doing Business in 2024: A Continued Legacy of Excellence
Q3 2024
-
What the Latest EPA PFAS Rule Means for Site Due Diligence
Q3 2024
-
Cold Storage: The Next Big Thing in Industrial Real Estate
Q3 2024
-
2023 Top States for Doing Business Meet the Needs of Site Selectors
Q3 2023
-
The Challenge of Securing Sufficient Electrical Power for Battery Cell Plants
Q3 2024
-
2023's Leading Metro Locations: Hotspots of Economic Growth
Q4 2023
-
Semiconductors’ Fragile Relationship With Water May Be Tested
Q3 2024